Research published in the European Journal of Neurology indicates that COVID-19 and COVID-19 vaccination have negligible effects on migraine severity. Among 550 adults who had received migraine-related care at a… read more.
Among patients with treatment resistant epilepsy, the investigative drug XEN1101 has reduced seizure frequency by over 50%. And in some patients it stops them completely. Researchers reported these… read more.
A UCSF telecare program that improves outcomes for patients with dementia and lightens the load for unpaid caregivers also has the surprising bonus of cutting Medicare costs, according… read more.
Attention-deficit/hyperactivity disorder (ADHD) is among the most common pediatric neurodevelopmental disorders. In 2019, nearly 10% of United States (U.S.) children had a diagnosis of ADHD. Approximately 3.3 million… read more.
On 14 September 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product… read more.
A new approach to electrically stimulating the brain can improve the gait of people with Parkinson’s disease (PD), according to a study by Shinshu University in Japan. The… read more.
European medicines regulators are studying the potential risk of neurodevelopmental disorders (NDDs) in children conceived by fathers taking valproate, an epilepsy medicine. Preliminary data suggest a possible association… read more.
Multiple studies have demonstrated the memory-enhancing effects of melatonin and its derivatives in animal models. It is also known that the formation of both short- and long-term memories… read more.
Higher testosterone levels during adolescence are associated with increased involvement of the brain’s anterior prefrontal cortex (aPFC) in emotion control, but the opposite effect occurs during adulthood. In… read more.
Neurologic illnesses, including Alzheimer’s, brain cancer, amyotrophic lateral sclerosis (ALS) and stroke, are among the most dreaded illnesses in medicine and leading causes of disability and death worldwide…. read more.
AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of atogepant for the… read more.
SK Biopharmaceuticals said that Health Canada granted a Notice of Compliance for Xcopri (ingredient: cenobamate), its epilepsy drug, approving its application for marketing authorization in Canada. Paladin Labs,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
